Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Korea's Celltrion Gains Foothold in Europe; Wins Clinical Trial Approval from Latvia For Herceptin Biosimilar

This article was originally published in PharmAsia News

Executive Summary

SEOUL - South Korea's Celltrion has secured an approval from EU member Latvia to perform clinical trials for its Herceptin (trastuzumab) biosimilar as part of its effort to prepare for the expiration of Roche's patent rights on the product in 2019 in Europe and the U.S

Related Content




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts